1-S-hexadecyl-2-O-methyl-rac-thioglycerol | 83518-62-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-S-hexadecyl-2-O-methyl-rac-thioglycerol
• 英文别名: 3-hexadecylthio-2-methoxypropan-1-ol；3-(Hexadecylsulfanyl)-2-methoxypropan-1-OL；3-hexadecylsulfanyl-2-methoxypropan-1-ol
• CAS: 83518-62-1
• 化学式: C₂₀H₄₂O₂S
• 分子量: 346.618
• InChiKey: MYQGHXAXDPWMQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  23
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-S-hexadecyl-2-O-methyl-rac-thioglycerol 在 三乙胺 、 三氯氧磷 作用下， 以 正己烷 、 甲苯 为溶剂， 以24%的产率得到(+/-)-3-(hexadecylthio)-2-methoxypropyl phosphate
  参考文献：
  名称：

  Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity

  摘要：

  Combinations of an amidoalkylphosphocholine, 8, and AZT have been found to cause an apparent synergistic action in suppressing infectious HIV-1 replication. In addition, amidoalkyl, oxyalkyl, and thioalkyl ether lipids have been chemically linked to anti-HIV-1 nucleosides (AZT and DDI) through phosphate and phosphonate linkages. These conjugates have shown promising in vitro anti-HIV-1 activity. Also, the conjugates have a 5-10-fold reduction in cell cytotoxicity compared to AZT alone. The most active compound, an amidoalkyl ether lipid-AZT conjugate, 4A, was found to have a differential selectivity of 1793 in a syncytial plaque assay. In comparison, AZT alone has a value of 1281.

  DOI：

  10.1021/jm00108a025
• 作为产物：
  描述：

  1-S-hexadecyl-3-O-trityl-rac-thioglycerol 在 sodium hydride 、 对甲苯磺酸 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 49.0h， 生成 1-S-hexadecyl-2-O-methyl-rac-thioglycerol
  参考文献：
  名称：

  新型的烷基甘油季铵盐衍生物作为蛋白激酶C的有效抑制剂的合成及生物活性

  摘要：

  烷基甘油，例如rac-1-O-十八烷基-2-O-甲基甘油磷酸胆碱（Et-18-OMe）对多种癌细胞系的转移和生长均显示出抑制作用。已显示烷基磷脂积聚在几种细胞系的表面，其选择性仍不清楚。该作用的结果可能导致抑制细胞膜相关蛋白激酶C（PKC）。这项研究的目的是开发PKC的醚脂质抑制剂以增强抗肿瘤活性。这导致了一系列烷基甘油的新型季铵衍生物的合成和体外测试。这些类似物在用rac-1-O-油酰基-2-O-乙酰甘油刺激的PKC上的生物学测试表明，其抑制作用与Et-18-OMe相当。

  DOI：

  10.1021/jm00165a016

文献信息

• Lipid derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US05047540A1

  公开（公告）日：1991-09-10

  Lipid derivatives represented by the formula: ##STR1## wherein R.sub.1 is alkyl or alkylcarbamoyl; R.sub.2 is lower alkyloxy, lower alkylcarbamoyloxy, lower alkylcarbonylamino, lower alkyloxycarbonylamino, lower alkylureido, lower alkyloxymethyl, lower alkylcarbonylmethyl, cyanomethyl, heterocyclic group, or he0 terocyclyloxy; R.sub.2 ' is hydrogen or R.sub.2 and R.sub.2 ' taken together form --O(CH.sub.2).sub.m -- wherein m is an integer of 1 to 5; R.sub.3, R.sub.4, and R.sub.5 each is hydrogen or lower alkyl or two or three of R.sub.3, R.sub.4, and R.sub.5 taken together with the adjacent nitrogen atom form cyclic ammonio; R.sub.6 is hydrogen or lower alkylcarbonyl; X.sup.- is a counter anion; Y is oxygen or sulfur; and n is an integer of 1 to 10, being useful as PAF antagonists, e.g., as antithrombotic, antivasoconstricting, antibronchoconstricting agent or antitumor agent.

  脂质衍生物的化学式表示为：##STR1## 其中 R.sub.1 是烷基或烷基氨基甲酰基；R.sub.2 是较低的烷氧基、较低的烷基氨基甲酰氧基、较低的烷基羰基氨基、较低的烷氧羰基氨基、较低的烷基脲基、较低的烷氧甲基、较低的烷基羰基甲基、氰甲基、杂环基团或杂环氧基；R.sub.2 ' 是氢或 R.sub.2 和 R.sub.2 ' 结合形成 --O(CH.sub.2).sub.m --，其中 m 是 1 到 5 的整数；R.sub.3、R.sub.4 和 R.sub.5 每个是氢或较低的烷基，或 R.sub.3、R.sub.4 和 R.sub.5 中的两个或三个与相邻的氮原子结合形成环状铵基；R.sub.6 是氢或较低的烷基羰基；X.sup.- 是一个对离子；Y 是氧或硫；n 是 1 到 10 的整数，可用作 PAF 拮抗剂，例如作为抗血栓、抗血管收缩、抗支气管收缩剂或抗肿瘤剂。
• Synthesis of sulfur analogs of alkyl lysophospholipid and neoplastic cell growth inhibitory properties
  作者：Susan Morris-Natschke、Jefferson R. Surles、Larry W. Daniel、Michael E. Berens、Edward J. Modest、Claude Piantadosi

  DOI：10.1021/jm00160a055

  日期：1986.10

  Five sulfur-containing phospholipid analogues (compounds 1-5) of alkyl lysophospholipid (1-O-alkyl-2-O-methyl-rac-glycero-3-phosphocholine, ALP) were synthesized and tested for inhibition of neoplastic cell proliferation with two human ovarian carcinoma cell lines in a clonogenic assay and with the HL-60 promyelocytic leukemia cell line. Compared with 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine

  合成了五个烷基溶血磷脂（1-O-烷基-2-O-甲基-rac-甘油-3-磷酸胆碱，ALP）的含硫磷脂类似物（化合物1-5），并用两种方法测试了对肿瘤细胞增殖的抑制作用人卵巢癌细胞系的克隆形成分析以及HL-60早幼粒细胞白血病细胞系。与最活跃的参考类似物1-O-十八烷基-2-O-甲基-rac-甘油-3-磷酸胆碱（ET-18-OMe）相比，这些硫代类似物对HL-60细胞的活性至少相同。 1-S-十六烷基-2-O-乙基类似物（2）在克隆形成测定中的活性是其两倍。
• A Novel Class of Platelet Activating Factor(PAF) Antagonists. I. Synthesis and Structure-Activity Studies on PAF-Sulfonamide Isosteres.
  作者：Tatsuo TSURI、Nobuhiro HAGA、Takeaki MATSUI、Susumu KAMATA、Hisato KAKUSHI、Kiyohisa UCHIDA

  DOI：10.1248/cpb.40.75

  日期：——

  New platelet activating factor (PAF) antagonists, 3 were synthesized by replacing the charged phosphate and trimethylammonium moieties with sulfonamide and heterocyclic quarternary ammonium functionalities, respectively(PAF-sulfonamide isosteres). Darmstoff phosphatidic acid analogues of this class (Darmstoff-sulfonamide isosteres), 6 were also synthesized.The activity of these compounds as PAF antagonists was evaluated from their in vitro inhibitory effect on PAF-induced platelet aggregation in rabbit platelet-rich plasma. Among the compounds tested, some of the 2-methoxypropane derivatives with an octadecylcarbamoyloxy or octadecylcarbamoylthio side chain at the 1-position and a propylsulfonamide function bearing a terminal polar substituent such as a quarternary quinolinium or substituted quinolinium group at the 3-position were found to be the most potent (IC50=0.3-0.6μM).

  通过分别用磺酰胺和杂环季铵官能团取代带电的磷酸盐和三甲基铵，合成了新的血小板活化因子（PAF）拮抗剂 3（PAF-磺酰胺异构体）。这些化合物作为 PAF 拮抗剂的活性是通过它们对 PAF 诱导的兔血小板富集血浆中血小板聚集的体外抑制作用来评估的。在测试的化合物中，一些 2-甲氧基丙烷衍生物的 1 位具有十八烷基氨基甲酰氧基或十八烷基氨基甲酰硫代侧链，3 位具有丙磺酰胺功能并带有末端极性取代基（如四元喹啉基或取代的喹啉基），这些化合物的效力最强（IC50=0.3-0.6μM）。
• Synthesis and biological activity of novel quaternary ammonium derivatives of alkylglycerols as potent inhibitors of protein kinase C
  作者：Canio J. Marasco、Claude Piantadosi、Karen L. Meyer、Susan Morris-Natschke、Khalid S. Ishaq、George W. Small、Larry W. Daniel

  DOI：10.1021/jm00165a016

  日期：1990.3

  effect on the metastasis and growth of various cancer cell lines. Alkyl phospholipids have been shown to accumulate at the surface in several cell lines, the selectivity of which is still not clearly understood. A consequence of this action may lead to the inhibition of cell membrane related protein kinase C (PKC). The goal of this research was to develop ether lipid inhibitors of PKC to augment antineoplastic

  烷基甘油，例如rac-1-O-十八烷基-2-O-甲基甘油磷酸胆碱（Et-18-OMe）对多种癌细胞系的转移和生长均显示出抑制作用。已显示烷基磷脂积聚在几种细胞系的表面，其选择性仍不清楚。该作用的结果可能导致抑制细胞膜相关蛋白激酶C（PKC）。这项研究的目的是开发PKC的醚脂质抑制剂以增强抗肿瘤活性。这导致了一系列烷基甘油的新型季铵衍生物的合成和体外测试。这些类似物在用rac-1-O-油酰基-2-O-乙酰甘油刺激的PKC上的生物学测试表明，其抑制作用与Et-18-OMe相当。
• [EN] NEW GLYCOLIPIDS AND USE THEREOF AS SK3 ION CHANNEL MODULATORS<br/>[FR] NOUVEAUX GLYCOLIPIDES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE CANAUX IONIQUES SK3
  申请人：UNIV BRETAGNE OCCIDENTALE

  公开号：WO2022013430A1

  公开（公告）日：2022-01-20

  The present invention relates to new glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.

  本发明涉及公式（I）的新型糖脂衍生物及其在治疗与SK3离子通道的表达和/或活性失调相关的疾病中的应用。本发明还涉及含有公式（I）化合物的药物组合物，用于治疗与SK3离子通道的表达和/或活性失调相关的疾病。